MCI-225 hydrochloride | 99487-26-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: MCI-225 hydrochloride
• 英文别名: 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride；Thieno(2,3-d)pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, monohydrochloride；4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine;hydrochloride
• CAS: 99487-26-0
• 化学式: C₁₇H₁₇FN₄S*ClH
• 分子量: 364.874
• InChiKey: ULXKGHLJAPRUPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.64
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  69.3
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
  申请人：Verheijen C. Jeroen

  公开号：US20050096387A1

  公开（公告）日：2005-05-05

  Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or diseases associated with a deficiency in a pharmacologically active agent, such as acetylcholine.

  碳酰基酯抑制胆碱酯酶活性，水解后释放出药理活性成分。在一种实施例中，碳酰基酯具有以下结构：其中A选自无取代芳基、取代芳基、无取代杂环芳基和取代杂环芳基的群组。碳酰基酯用于治疗个体的方法中。通过水解碳酰基酯获得的药理活性成分可以治疗例如神经系统疾病、胆碱能缺乏以及与药理活性成分缺乏相关的疾病或病症，例如乙酰胆碱。
• Soluble salts of thieno[2,3-d]pyrimidine derivatives
  申请人：Cooper Ian Martin

  公开号：US20070254899A1

  公开（公告）日：2007-11-01

  The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

  本发明涉及噻唑[2,3-d]嘧啶衍生物的新型盐，包括4-(2-氟苯基)-6-甲基-2-(哌嗪-1-基)噻唑[2,3-d]嘧啶盐。本发明还涉及包含这种多晶体的组合物以及使用这种盐的方法，例如在治疗胃肠和/或泌尿系统疾病中的应用。
• CRYSTALLINE FORMS OF 4-(2-FLUOROPHENYL)-6-METHYL-2-(PIPERAZIN-1-YL)THIENO(2,3-D)PYRIMIDINE
  申请人：Dynogen Pharmaceuticals, Inc.

  公开号：EP2016082A2

  公开（公告）日：2009-01-21
• COMPOUNDS THAT INHIBIT CHOLINESTERASE
  申请人：Colucid Pharmaceuticals, Inc.

  公开号：EP2125709A2

  公开（公告）日：2009-12-02
• Crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine
  申请人：Cooper Ian Martin

  公开号：US20070254891A1

  公开（公告）日：2007-11-01

  The present invention is directed to novel crystalline forms of 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine hydrochloride crystalline forms. The present invention is also directed to compositions including such crystalline forms and methods for making and using such crystalline forms, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.